Author | Year | Country | Ethnicity | Cancer type | Genotyping method | Control | Cases/control | Cases | Control | HWE | NOS | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
aa | ag | gg | aa | ag | gg | ||||||||||
Mackawy | 2019 | Egypt | Arabian | Ovarian carcinoma | PCR–RFLP | HB | 50/20 | 14 | 20 | 16 | 4 | 6 | 10 | 0.128 | 6 |
Pei | 2018 | China | Asian | Acute lymphoblastic leukemia | PCR–RFLP | PB | 266/266 | 55 | 144 | 67 | 53 | 150 | 63 | 0.035 | 7 |
Al Zoubi | 2017 | Italy | Caucasian | Breast cancer | Sequencing | HB | 23/16 | 8 | 14 | 1 | 11 | 5 | 0 | 0.459 | 7 |
De Mattia | 2017 | Italy | Caucasian | Hepatocellular cancer | TaqMan | HB | 192/192 | 128 | 52 | 12 | 137 | 49 | 5 | 0.806 | 7 |
Sarwar | 2017 | Pakistan | Asian | Thyroid cancer | ARMS-PCR | HB | 456/400 | 289 | 90 | 77 | 297 | 65 | 38 | < 0.001 | 7 |
Yan | 2016 | China | Asian | Yhyroid carcinoma | PCR | HB | 276/403 | 116 | 127 | 33 | 202 | 161 | 40 | 0.345 | 8 |
Zhu | 2016 | China | Asian | Bladder cancer | TaqMan | HB | 184/260 | 72 | 53 | 59 | 69 | 142 | 49 | 0.111 | 7 |
Ali | 2016 | Saudi Arabia | Arabian | Breast cancer | PCR–RFLP | HB | 143/145 | 102 | 40 | 1 | 93 | 28 | 24 | < 0.001 | 7 |
Chang | 2015 | China | Asian | Leiomyoma | PCR–RFLP | HB | 166/474 | 35 | 91 | 40 | 93 | 268 | 113 | 0.004 | 7 |
Chen | 2015 | China | Asian | Lung cancer | PCR–RFLP | HB | 358/716 | 70 | 202 | 86 | 147 | 395 | 177 | 0.007 | 7 |
Liu | 2015 | China | Asian | Nasopharyngeal carcinoma | PCR–RFLP | HB | 176/880 | 33 | 99 | 44 | 179 | 489 | 212 | 0.001 | 7 |
Su | 2015 | China | Asian | Breast cancer | PCR–RFLP | HB | 1232/1232 | 239 | 696 | 297 | 254 | 668 | 310 | 0.002 | 8 |
Al Zoubi | 2015 | Jordan | Arabian | Breast cancer | Sequencing | HB | 46/31 | 16 | 28 | 2 | 21 | 9 | 1 | 0.976 | 7 |
Yuan | 2015 | China | Asian | Papillary thyroid cancer | PCR | HB | 183/367 | 77 | 84 | 22 | 184 | 147 | 36 | 0.406 | 6 |
Goričar | 2015 | Slovenia | Caucasian | Acute lymphoblastic leukemia | TaqMan | PB | 121/184 | 89 | 117 | ≥ 0.050 | 8 | ||||
Goričar | 2015 | Slovenia | Caucasian | Osteosarcoma | TaqMan | PB | 79/373 | 47 | 247 | ND | 7 | ||||
Smolkova | 2014 | Germany | Caucasian | Acute lymphoblastic leukaemia | TaqMan | HB | 460/547 | 286 | 155 | 19 | 340 | 183 | 24 | 0.921 | 7 |
TSAI | 2014 | China | Asian | Oral cancer | PCR–RFLP | HB | 788/956 | 155 | 438 | 195 | 195 | 532 | 229 | < 0.001 | 7 |
He | 2013 | China | Asian | Lung cancer | PCR | HB | 507/661 | 180 | 230 | 97 | 184 | 313 | 164 | 0.181 | 7 |
Zhao | 2013 | China | Asian | Glioma | TaqMan | HB | 384/384 | 83 | 201 | 100 | 95 | 181 | 108 | 0.271 | 7 |
Gresner | 2012 | Poland | Caucasian | Head and neck cancer | PCR–RFLP | PB | 81/100 | 45 | 31 | 5 | 59 | 34 | 7 | 0.497 | 8 |
VRAL | 2011 | Belgium | Caucasian | Breast cancer | PCR–RFLP or SnapShot technique | HB | 343/172 | 220 | 108 | 15 | 117 | 52 | 3 | 0.304 | 5 |
Quaye | 2009 | mixed | Caucasian | Ovarian cancer | TaqMan | PB | 1461/2307 | 940 | 484 | 37 | 1505 | 713 | 89 | 0.691 | 8 |
Andrew | 2009 | USA | Mixed | Bladder cancer | PCR–RFLP | PB | 342/559 | 190 | 333 | ND | 7 | ||||
Hayden | 2007 | Germany, Italy, Spain, Ireland,France, Czech Republic and the Irish | Caucasian | Myeloma | TaqMan | Mixed | 302/257 | 189 | 100 | 13 | 153 | 91 | 13 | 0.911 | 8 |
Ni | 2006 | China | Asian | Thyroid carcinoma | PCR–RFLP | HB | 191/201 | 66 | 81 | 44 | 62 | 94 | 45 | 0.411 | 7 |
Garcıa-Closas | 2006 | Poland | Caucasian | Breast cancer | ND | PB | 1920/2218 | 1210 | 632 | 78 | 1386 | 736 | 96 | 0.891 | 8 |
Garcıa-Closas | 2006 | USA | Caucasian | Breast cancer | ND | PB | 1564/1264 | 980 | 521 | 63 | 837 | 357 | 52 | 0.079 | 8 |
Wu | 2006 | USA | Mixed | Bladder cancer | PCR–RFLP | HB | 599/595 | 402 | 185 | 12 | 398 | 185 | 12 | 0.072 | 8 |
Paul Pharoah ICRC-Thai | 2006 | Thailand | Asian | Breast cancer | ND | PB | 465/389 | 153 | 217 | 95 | 135 | 182 | 72 | 0.441 | 8 |
Paul Pharoah SEARCH | 2006 | UK | Caucasian | Breast cancer | ND | PB | 2790/3642 | 1808 | 889 | 93 | 2388 | 1113 | 141 | 0.427 | 8 |
Paul Pharoah Sheffield | 2006 | UK | Caucasian | Breast cancer | ND | HB | 1185/1159 | 781 | 369 | 35 | 755 | 353 | 51 | 0.238 | 8 |
Paul Pharoah USRTS | 2006 | USA | Caucasian | Breast cancer | ND | Nested | 718/1049 | 458 | 224 | 36 | 650 | 356 | 43 | 0.509 | 8 |
Auranen1 | 2005 | US FROC | Caucasian | Ovarian cancer | TaqMan | PB | 325/417 | 204 | 112 | 9 | 267 | 133 | 17 | 0.932 | 8 |
Auranen2 | 2005 | UK RMH/YOV | Caucasian | Ovarian cancer | TaqMan | PB | 301/1808 | 194 | 95 | 12 | 1196 | 535 | 77 | 0.083 | 8 |
Matullo | 2005 | Italy | Caucasian | Bladder cancer | PCR–RFLP | HB | 316/315 | 207 | 98 | 11 | 201 | 102 | 12 | 0.833 | 7 |
Han | 2004 | USA | Caucasian | Breast cancer | TaqMan | PB | 991/1291 | 630 | 322 | 39 | 865 | 372 | 54 | 0.084 | 8 |
Han | 2004 | USA | Caucasian | Endometrial cancer | TaqMan | PB | 220/663 | 140 | 73 | 7 | 438 | 200 | 25 | 0.716 | 8 |
Jacobsen | 2004 | Denmark | Caucasian | Lung cancer | PCR | Nested | 256/269 | 111 | 116 | 29 | 108 | 127 | 34 | 0.724 | 8 |
Tranah | 2004 | USA (NHS) | Caucasian | Colorectal adenoma | TaqMan | Nested | 556/557 | 256 | 212 | 58 | 250 | 222 | 54 | 0.65 | 8 |
Tranah | 2004 | USA (HPFS) | Caucasian | Colorectal adenoma | TaqMan | Nested | 376/725 | 180 | 155 | 31 | 329 | 303 | 73 | 0.793 | 8 |
Kuschel | 2002 | UK | Caucasian | Breast cancer | TaqMan | PB | 1828/1808 | 1176 | 581 | 71 | 1196 | 535 | 77 | 0.083 | 8 |
Winsey | 2000 | UK | Caucasian | Melanoma skin cancer | PCR-SSP | HB | 125/211 | 5 | 47 | 73 | 8 | 80 | 122 | 0.245 | 7 |